Effectiveness of lanthanum carbonate treatment used in combination with other phosphate binders in peritoneal dialysis patients

Shunsuke Yamada, Hisako Yoshida, Masatomo Taniguchi, Shigeru Tanaka, Masahiro Eriguchi, Toshiaki Nakano, Kazuhiko Tsuruya, Takanari Kitazono

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective Phosphate binders are used in the treatment of hyperphosphatemia in peritoneal dialysis (PD) patients. An ideal phosphate binder for long-term use must be effective with little or no side effects. We evaluated the long-term efficacy and side effects of lanthanum carbonate (LaC) used in combination with other phosphate binders in PD patients. Patients The subjects of this retrospective study were 30 PD patients who received LaC at Kyushu University. The effect of LaC on various biochemical parameters (serum phosphate, calcium and parathyroid hormone), daily dose of other phosphate binders, gastrointestinal side effects, and nutritional status were determined during the 24-week treatment. We also evaluated the rate of achievement of the Japanese Society of Dialysis Treatment guidelines for secondary hyperparathyroidism and used multivariate analysis to determine the factors associated with the efficacy of LaC. Results LaC (960±412 mg/day) reduced serum phosphate from 6.2 to 5.3 mg/dL. The rate of achievement of the guideline target improved after 24 weeks of LaC treatment. The dose of other phosphate binders and dialysis volume remained unchanged during the treatment. Although 53% of patients experienced at least one gastrointestinal side effect, LaC treatment did not affect the nutritional status, and none of the patients discontinued LaC. Multivariate analysis identified low stature, old age and high baseline total creatinine clearance as significant factors that determine the effectiveness of LaC in PD patients. Conclusion Low dose LaC treatment used in combination with other phosphate binders improved serum phosphate control with tolerable gastrointestinal symptoms in PD patients.

Original languageEnglish (US)
Pages (from-to)2097-2104
Number of pages8
JournalInternal Medicine
Volume51
Issue number16
DOIs
StatePublished - 2012

Fingerprint

Peritoneal Dialysis
Phosphates
Therapeutics
Nutritional Status
Dialysis
Multivariate Analysis
Serum
lanthanum carbonate
Guidelines
Hyperphosphatemia
Secondary Hyperparathyroidism
Parathyroid Hormone
Creatinine
Retrospective Studies

Keywords

  • Hyperphosphatemia
  • Lanthanum carbonate
  • Nutrition
  • Peritoneal dialysis
  • Phosphate binder

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Effectiveness of lanthanum carbonate treatment used in combination with other phosphate binders in peritoneal dialysis patients. / Yamada, Shunsuke; Yoshida, Hisako; Taniguchi, Masatomo; Tanaka, Shigeru; Eriguchi, Masahiro; Nakano, Toshiaki; Tsuruya, Kazuhiko; Kitazono, Takanari.

In: Internal Medicine, Vol. 51, No. 16, 2012, p. 2097-2104.

Research output: Contribution to journalArticle

Yamada, S, Yoshida, H, Taniguchi, M, Tanaka, S, Eriguchi, M, Nakano, T, Tsuruya, K & Kitazono, T 2012, 'Effectiveness of lanthanum carbonate treatment used in combination with other phosphate binders in peritoneal dialysis patients', Internal Medicine, vol. 51, no. 16, pp. 2097-2104. https://doi.org/10.2169/internalmedicine.51.6814
Yamada, Shunsuke ; Yoshida, Hisako ; Taniguchi, Masatomo ; Tanaka, Shigeru ; Eriguchi, Masahiro ; Nakano, Toshiaki ; Tsuruya, Kazuhiko ; Kitazono, Takanari. / Effectiveness of lanthanum carbonate treatment used in combination with other phosphate binders in peritoneal dialysis patients. In: Internal Medicine. 2012 ; Vol. 51, No. 16. pp. 2097-2104.
@article{e92fa31f931341e6b0fb536333391b32,
title = "Effectiveness of lanthanum carbonate treatment used in combination with other phosphate binders in peritoneal dialysis patients",
abstract = "Objective Phosphate binders are used in the treatment of hyperphosphatemia in peritoneal dialysis (PD) patients. An ideal phosphate binder for long-term use must be effective with little or no side effects. We evaluated the long-term efficacy and side effects of lanthanum carbonate (LaC) used in combination with other phosphate binders in PD patients. Patients The subjects of this retrospective study were 30 PD patients who received LaC at Kyushu University. The effect of LaC on various biochemical parameters (serum phosphate, calcium and parathyroid hormone), daily dose of other phosphate binders, gastrointestinal side effects, and nutritional status were determined during the 24-week treatment. We also evaluated the rate of achievement of the Japanese Society of Dialysis Treatment guidelines for secondary hyperparathyroidism and used multivariate analysis to determine the factors associated with the efficacy of LaC. Results LaC (960±412 mg/day) reduced serum phosphate from 6.2 to 5.3 mg/dL. The rate of achievement of the guideline target improved after 24 weeks of LaC treatment. The dose of other phosphate binders and dialysis volume remained unchanged during the treatment. Although 53{\%} of patients experienced at least one gastrointestinal side effect, LaC treatment did not affect the nutritional status, and none of the patients discontinued LaC. Multivariate analysis identified low stature, old age and high baseline total creatinine clearance as significant factors that determine the effectiveness of LaC in PD patients. Conclusion Low dose LaC treatment used in combination with other phosphate binders improved serum phosphate control with tolerable gastrointestinal symptoms in PD patients.",
keywords = "Hyperphosphatemia, Lanthanum carbonate, Nutrition, Peritoneal dialysis, Phosphate binder",
author = "Shunsuke Yamada and Hisako Yoshida and Masatomo Taniguchi and Shigeru Tanaka and Masahiro Eriguchi and Toshiaki Nakano and Kazuhiko Tsuruya and Takanari Kitazono",
year = "2012",
doi = "10.2169/internalmedicine.51.6814",
language = "English (US)",
volume = "51",
pages = "2097--2104",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "16",

}

TY - JOUR

T1 - Effectiveness of lanthanum carbonate treatment used in combination with other phosphate binders in peritoneal dialysis patients

AU - Yamada, Shunsuke

AU - Yoshida, Hisako

AU - Taniguchi, Masatomo

AU - Tanaka, Shigeru

AU - Eriguchi, Masahiro

AU - Nakano, Toshiaki

AU - Tsuruya, Kazuhiko

AU - Kitazono, Takanari

PY - 2012

Y1 - 2012

N2 - Objective Phosphate binders are used in the treatment of hyperphosphatemia in peritoneal dialysis (PD) patients. An ideal phosphate binder for long-term use must be effective with little or no side effects. We evaluated the long-term efficacy and side effects of lanthanum carbonate (LaC) used in combination with other phosphate binders in PD patients. Patients The subjects of this retrospective study were 30 PD patients who received LaC at Kyushu University. The effect of LaC on various biochemical parameters (serum phosphate, calcium and parathyroid hormone), daily dose of other phosphate binders, gastrointestinal side effects, and nutritional status were determined during the 24-week treatment. We also evaluated the rate of achievement of the Japanese Society of Dialysis Treatment guidelines for secondary hyperparathyroidism and used multivariate analysis to determine the factors associated with the efficacy of LaC. Results LaC (960±412 mg/day) reduced serum phosphate from 6.2 to 5.3 mg/dL. The rate of achievement of the guideline target improved after 24 weeks of LaC treatment. The dose of other phosphate binders and dialysis volume remained unchanged during the treatment. Although 53% of patients experienced at least one gastrointestinal side effect, LaC treatment did not affect the nutritional status, and none of the patients discontinued LaC. Multivariate analysis identified low stature, old age and high baseline total creatinine clearance as significant factors that determine the effectiveness of LaC in PD patients. Conclusion Low dose LaC treatment used in combination with other phosphate binders improved serum phosphate control with tolerable gastrointestinal symptoms in PD patients.

AB - Objective Phosphate binders are used in the treatment of hyperphosphatemia in peritoneal dialysis (PD) patients. An ideal phosphate binder for long-term use must be effective with little or no side effects. We evaluated the long-term efficacy and side effects of lanthanum carbonate (LaC) used in combination with other phosphate binders in PD patients. Patients The subjects of this retrospective study were 30 PD patients who received LaC at Kyushu University. The effect of LaC on various biochemical parameters (serum phosphate, calcium and parathyroid hormone), daily dose of other phosphate binders, gastrointestinal side effects, and nutritional status were determined during the 24-week treatment. We also evaluated the rate of achievement of the Japanese Society of Dialysis Treatment guidelines for secondary hyperparathyroidism and used multivariate analysis to determine the factors associated with the efficacy of LaC. Results LaC (960±412 mg/day) reduced serum phosphate from 6.2 to 5.3 mg/dL. The rate of achievement of the guideline target improved after 24 weeks of LaC treatment. The dose of other phosphate binders and dialysis volume remained unchanged during the treatment. Although 53% of patients experienced at least one gastrointestinal side effect, LaC treatment did not affect the nutritional status, and none of the patients discontinued LaC. Multivariate analysis identified low stature, old age and high baseline total creatinine clearance as significant factors that determine the effectiveness of LaC in PD patients. Conclusion Low dose LaC treatment used in combination with other phosphate binders improved serum phosphate control with tolerable gastrointestinal symptoms in PD patients.

KW - Hyperphosphatemia

KW - Lanthanum carbonate

KW - Nutrition

KW - Peritoneal dialysis

KW - Phosphate binder

UR - http://www.scopus.com/inward/record.url?scp=84865129419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865129419&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.51.6814

DO - 10.2169/internalmedicine.51.6814

M3 - Article

VL - 51

SP - 2097

EP - 2104

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 16

ER -